Question 1

What is VXV-01?

Accepted Answer

VXV-01 is a Other.

Question 2

How often does VXV-01 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was VXV-01 first tracked by Ergen?

Accepted Answer

First tracked on Jul 03, 2026.

Question 4

When was VXV-01 last mentioned in news?

Accepted Answer

Last active on Jul 04, 2026.

Question 5

What is VXV-01's current news sentiment?

Accepted Answer

Aggregate sentiment score: -80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is VXV-01 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving VXV-01?

Accepted Answer

Appili Therapeutics VXV-01 Contract Terminated (Jul 03, 2026, 7 articles).

Question 8

How did the "Appili Therapeutics VXV-01 Contract Terminated" event impact VXV-01?

Accepted Answer

VXV-01, a fungal vaccine candidate, is the subject of the terminated contract, halting its development under the Norway — Norwegian Institute of Public Health funding.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.